Chinese herbal medicine (Tuhuai extract) exhibits topical anti-proliferative and anti-inflammatory activity in murine disease models

Experimental Dermatology

Volumn 17, Issue 8, 2008, Pages 681-687

  Man, Mao Qiang ^a,b   Shi, Yuejun ^a   Man, Mona ^b   Lee, Seung Hun ^c   Demerjian, Marianne ^b   Chang, Sandra ^b   Feingold, Kenneth R ^b   Elias, Peter M ^b,d  

^a Dalian Skin Disease Hospital   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Yonsei University   (South Korea)

^d Dermatology Service 190   (United States)

Author keywords

Chinese herbal medicine; Epidermal proliferation; Inflammation; Psoriasis

Indexed keywords

CHINESE DRUG; OXAZOLONE; PHORBOL ESTER; TUHUAI;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHINESE MEDICINE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EPIDERMIS; EPIDERMIS CELL; EPIDERMIS HYPERPLASIA; FEMALE; IMMUNOHISTOCHEMISTRY; MOUSE; NICK END LABELING; NONHUMAN; PSORIASIS; SKIN ALLERGY; SKIN DISEASE; TREATMENT DURATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CELL PROLIFERATION; DERMATITIS, ALLERGIC CONTACT; DERMATITIS, CONTACT; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; FABACEAE; FEMALE; GLYCYRRHIZA; HUMANS; HYPERPLASIA; MALE; MICE; MICE, INBRED HRS; OXAZOLONE; PHYTOTHERAPY; PSORIASIS; SKIN; SMILAX; TETRADECANOYLPHORBOL ACETATE;

EID: 47949107388     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2007.00690.x     Document Type: Article

References (66)

1. Mueller W, Hermann B. Cyclosporin A for psoriasis. N Engl J Med 1979: 301: 355.
2. Griffiths CE, Powles AV, Leonard JN, Fry L, Baker BS, Valdimarsson H. Clearance of psoriasis with low dose cyclosporin. Br Med J 1986: 293: 731-732.
3. Korstanje MJ, Bilo HJG, Stoof TJ. Sustained renal function loss in psoriasis patients after withdrawal of low dose cyclosporin therapy. Br J Dermatol 1992: 127: 501-504.
4. Powles AV, Hardman CM, Porter WM, Cook T, Hulme B, Fry L. Renal function after 10 years treatment with cyclosporin for psoriasis. Br J Dermatol 1998: 138: 443-449.
5. Oettinger-Barak O, Machtei EE, Peled M, Barak S, L-Naaj IA, Laufer D. Cyclosporine A-induced gingival hyperplasia pemphigus vulgaris: literature review and report of a case. J Periodontol 2000: 71: 650-656.
6. Kirby B, Rogers S. Gingival hyperplasia in psoriasis patients treated with cyclosporin. Clin Exp Dermatol 2000: 25: 97-98.
7. Markham T, Watson A, Rogers S. Adverse effects with long-term cyclosporin for severe psoriasis. Clin Exp Dermatol 2002: 27: 111-114.
8. V'lckova-Laskoska MT. Cyclosporin A-induced gingival hyperplasia in psoriasis: Review of literature and case reports. Acta Dermatovenerol Croat 2005: 13: 108-113.
9. Kolbe L, Kligman AM, Schreiner V, Stoudemayer T. Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Res Technol 2001: 7: 73-77.
10. Kumaran MS, Kaur I, Kumar B. Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol 2006: 20: 269-273.
11. Kragballe K, Austad J, Barnes L et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006: 154: 1155-1160.
12. Ahn SK, Bak HN, Park BD et al. Effects of a multilamellar emulsion on glucocorticoid-induced epidermal atropgy and barrier impairment. J Dermatol 2006: 33: 80-90.
13. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: A meta-analysis. Am J Med 1991: 90: 711-716.
14. Malatjialian DA, Ross JB, Williams CN, Colwell SJ, Eastwood BJ. Methotrexate hepatoxicity in psoriatics: Report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996: 10: 369-375.
15. Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthrithis and psoriatic arthritis. Clin Drug Invest 2006: 26: 55-62.
16. Cranney AB, McKendry RJ, Wells GA et al. The effect of low dose methotrexate on bone density. J Rheumatol 2001: 28: 2395-2399.
17. Minaur NJ, Kounali D, Vedi S, Compston JE, Beresford JN, Bhalla AK. Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology (Oxford) 2002: 41: 741-749.
18. Baker JN, Ashton RE, Marks R, Harris RI, Berth-Jones J. Topical maxacalcitol for the treatment of psoriasis vulgaris: A placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol 1999: 141: 274-278.
19. Van de Kerkhof PCM, Berth-Jones J, Griffiths CEM et al. Long-term efficacy and safety of tacalcitl ointment in patients with thronic plaque psoriasis. Br J Dermatol 2002: 146: 414-422.
20. Georgiou S, Tsambaos D. Hypercalcaemia and hypercalciuria after topical treatment of psoriasis with excessive amounts of calcipotriol. Acta Derm Venereol 1999: 79: 86.
21. Kawahara C, Okada Y, Tanikawa T, Fukusima A, Misawa H, Tanaka Y. Severs hypercalcaemia and hypercalciuria associated with calcipotriol for treatment of psoriasis. J bone Miner Metab 2004: 22: 159-162.
22. Goldfarb MT, Ellis CN, Gupta AK, Tincoff T, Hamilton TA, Voorhees JJ. Acitretin improves psoriasis in a dose-dependent fashion. J Am Acad Dermatol 1988: 18: 655-662.
23. Kragballe K, jansen CT, Geiger JM et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicenter study. Acta Derm Venereol 1989: 69: 35-40.
24. Gupta AK, Goldfarb MT, Ellis CN, Voorhees JJ. Aide-effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol 1989: 20: 1088-1093.
25. Pearce DJ, Higgins KB, Stealey KH et al. Adverse events from systemic therapies for psoriasis are common in clinical practice. J Dermatolog Treat 2006: 17: 288-293.
26. Kary S, Worm M, Audring H et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumor mecrosis factor alpha antagonists. Ann Rheum Dis 2006: 65: 405-407.
27. Roux CH, Brocq O, Leccia N et al. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: A class effect?. J Rheumatol 2007: 34: 434-437.
28. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003: 349: 2014-2022.
29. Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol 2005: 152: 1304-1312.
30. Bissonnette R. Etanercept for the treatment of psoriasis. Skin Therapy Lett 2006: 11: 1-4.
31. Tobin AM, Kirby B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs 2005: 19: 47-57.
32. Feldman SR, Evans C, Russell MW. Systemic treatment for moderate to severe psoriasis: Estimates of failure rates and direct medical costs in a north-eastern US managed care plan. J Dermatolog Treat 2005: 16: 37-42.
33. Liu HT, Zhang JM, Wang F et.al. Clinical study on Quyinheji for treatment of psoriasis. J Binzhou Med College 2002: 25: 341-342 (in Chinese).
34. Li HW, Zhang JA. Clinical observation of psoralen in the treatment of psoriasis. Chin J Dermatolvenereol 2006: 20: 640-641 (in Chinese).
35. Ye XY, Li XQ, Zhao JJ. Efficacy of SNMC in treatment of psoriasis vulgaris. Chin J Dermatovenereol 2006: 20: 128-128.
36. Zhang JM, Zhang YJ, Wang F, Han ZD, Zhou SH, Song M. Study on the effects of Xiaoyin mixture on epidermal cell proliferation, immunomodulation in mouse and bacteriostasis. Chin J Leprosy Skin Dis 2005: 21: 698-700 (in Chinese).
37. Bonder RH, Van Scott EJ. Use of mouse vaginal and rectal epithelium to screen antimitotic effects of systemically administered drugs. Cancer Res 1971: 31: 851-853.
38. Sheu MY, Fowler AJ, Kao J et.al. Topical peroxisome proliferator activated receptor-α activators reduce inflammation in irritant and allergic contact dermatitis models. J Invest Dermatol 2002: 118: 94-101.
39. Komuves LG, Hanley K, Man MQ, Elias PM, Williams ML, Feingold KR. Keratinocyte differentiation in hyperproliferative epidermis: Topical application of PPAR alpha activators restores tissue homoestasis. J Invest Dermatol 2000: 115: 361-367.
40. Mao-Qiang M, Fowler AJ, Schmuth M et.al. Peroxisome-proliferator-activated receptor (PPAR)-γ activation stimulation keratinocyte differentiation. J Invest Dermatol 2004: 123: 305-312.
41. Fowler AJ, Sheu MY, Schmuth M et al. LXR avtivators display anti-inflammatory activity in irritant and allergic contact dermatitis models. J Invest Dermatol 2003: 120: 246-255.
42. Hou PJ, Zhang JM. Treated of psoriasis with Tuhuai drink. Shandong J Traditional Chin Med 2002: 21: 311 (in Chinese).
43. Gong SM, Shi YJ. Clinical observation of psoriasis treated with the combination of Tuhuai and UVA+UVA. J Dermatol Venereol 2003: 25: 28-29 (in Chinese).
44. Tse WP, Che CT, Liu K, Lin ZX. Evaluation of the anti-proliferative properties of selected psoriasis-treating Chinese medicines on cultured HaCaT cells. J Ethnopharm 2006: 108: 133-141.
45. Wang Y, Bai CC, Gao WT, Xia YK. Experimental study on the treatment of psoriasis with Tuhuai. Chin J Leprosy Skin Dis 2006: 22: 297-298 (in Chinese).
46. Zhang RZ, Zhu WY, Ma J, Jin HL, Han HF. The effect of complex glycyrrhizin on the keratinocytes cultured in vitro. Chin J Dermatovenereol 2006: 20: 267-269 (in Chinese).
47. Goh D, Lee YH, Ong ES. Inhibitory effects of a chemically standardized extract from scutellaria barbata in human colon cancer cell lines, LoVo. J Agric Food Chem 2005: 53: 8197-8204.
48. Xu SP, Sun GP, Shen YX, Wei W, Peng WR, Wang H. Antiproliferation and apoptosis induction of paeonol in HepG2 cells. World J Gastroenterol 2007: 13: 250-256.
49. Tan S, Ye J, Qian C, Ji C, Liu C, Wang J. Paeonol inhibits the proliferation of human colorectal carcinoma cells and synergic with chemotherapeutic agents. Saudi J 2007: 28: 642-643.
50. Hogan FS, Krishnegowda NK, Mikhailova M, Kahlenber MS. Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. J Surg Res 2007: 143: 58-65.
51. El-Domyati M, Barakat M, Abdel-Razek R, El-Din Anbar T. Apoptosis, P53 and Bcl-2 expression in response to topical calcipotriol therapy for psoriasis. Int J Dermatol 2007: 46: 468-474.
52. Kruger-Krasagakis S, Galanopoulos Vk, Giannikaki L, Stefanidou M, Tosca AD. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis. Br J Dermatol 2006: 154: 460-466.
53. Zhang JM, Wang XM, Liu HT. Clinical observation of psoriasis vulgaris treated with Xiaoyin mixture. Chin J Leprosy Skin Dis 2004: 20: 249 (in Chinese).
54. Long LP, Bai YP, Liu YS et al. Observation on the effect of glycyrrhizin complex on subacute and chronic eczema. China Pharmacy 2003: 14: 37-38.
55. Saeedi M, Morteza-Semnani K, Ghoreishi MR. The treatment of atopic dermatitis with licorice gel. J Dermatolog Treat 2003: 14: 153-157.
56. Abramovits W, Boguniewicz M. A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. J Drugs Dermatol 2006: 5: 236-244.
57. Belloni G, Pinelli S, Veraldi S. A randomised, double-blind, vehicle-controlled study to evaluate the efficacy and safety of MAS063DP (Atopiclair) in the treatment of mild to moderate atopic dermatitis. Eur J Dermatol 2005: 15: 31-36.
58. Kawashima S, Hayashi M, Takii T et.al. Serontonin derivative N-(p-coumaroyl)- serotonin inhibits the production of TNF-α, IL-1α, IL-1β and IL-6 by endotoxin-stimulated human blood monocytes. J Interferon Cyt Res 1998: 18: 423-428.
59. Xu Q, Yuan K, Lu J. A new strategy for regulating the immunological liver injury-effectiveness of DTH-inhibiting agents on DTH-induced liver injury to picryl chloride. Pharmacol Res 1997: 36: 401-409.
60. Jiang J, Wu F, Lu J, Lu Z, Xu Q. Anti-inflammatory activity of the aqueous extract from Rhizoma smilacis glabrae. Pharmacol Res 1997: 36: 309-314.
61. Jiang J, Xu Q. Immunomodulatory activity of the aqueous extract from rhizome of smilax glabra in the later phase of adjuvant-induced arthritis in rats. J Ethnopharmacol 2003: 85: 53-59.
62. Fei M, Wu X, Xu Q. Astilbin inhibits contact hypersensitivity through negative cytokine regulation distinct cyclosporin A. J Allergy Clin Immunol 2005: 116: 1350-1356.
63. Cai Y, Chen T, Xu Q. Astilbin suppresses delayed-type hypersensitivity by inhibiting lymphocyte migration. J Pharm Pharmacol 2003: 55: 691-696.
64. Cai Y, Chen T, Xu Q. Astilbin suppresses collagen-induced arthritis via the dysfunction of lymphocytes. Inflamm Res 2003: 52: 334-340.
65. Tu CX, Zhang XJ, Zhang YY et al. Clinical and experimental study on treatment of atopic dermatitis with glycyrrhizin. Chin J Leprosy Skin Dis 2007: 23: 393-395 (in Chinese).
66. Demerijian M, Man MQ, Choi EH et al. Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model. Exp Dermatol 2006: 15: 154-160.